Three-Drug showdown aims to end stent pain for kidney stone patients

NCT ID NCT06803030

Recruiting now Symptom relief Sponsor: Bir Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares three common drugs—tamsulosin, solifenacin, and mirabegron—to see which one works best for reducing symptoms caused by ureteral stents placed after kidney stone surgery. About 189 adults will take one of the three pills daily and report their symptoms using a questionnaire. The goal is to find the most effective option to improve comfort while the stent is in place.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tamsulosin, solifenacin, mirabegron
What this could lead to: If successful, this could identify the best drug to reduce pain and urinary symptoms caused by ureteral stents, improving comfort for patients after stone surgery.
What could go wrong: This is a moderate-sized Phase 3 trial, but results may not apply to all stent patients. The drugs have known side effects like dry mouth or dizziness, and the best option may still leave some symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URETERAL STENT-RELATED SYMPTOM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URETERAL STENT-RELATED SYMPTOM

Contacts and locations

Locations

NAMS, Bir Hospital
RECRUITING

Kathmandu, Bagmati, 44600, Nepal

More trials for these conditions

Other studies related to the condition(s) this trial covers.